Table 1.
Inhibition of apoptosis by Bcl-xL–DTR
| Cell line | STS concentration, μM | Concentration of Bcl-xL–DTR, μM | Time of STS treatment, hr | Apoptosis prevention, %* | DT IC50, M |
|---|---|---|---|---|---|
| Cos-7 (monkey kidney) | 0.1 | 4.8 | 12 | 58.4 | 10−12–10−11 |
| U251 (human glioma) | 0.1 | 4.68 | 16 | 57.5 | 10−12–10−11 |
| HeLa (human cervical Ca) | 0.2 | 2.17 | 10 | 32.4 | 10−12–10−11 |
| Jurkat (human T leukemia) | 0.1 | 4.68 | 12 | 21.2 | 10−9 |
| 9L (rat gliosarcoma) | 0.1 | 4.68 | 12 | −5.4 | >10−7 |
| WEHI7.1 (mouse T lymphoma) | 0.1 | 4.68 | 12 | 0.5 | >10−7 |
*
Apoptotic cells were counted with Hoechst dye no. 33342, and the percentage prevention from apoptosis was calculated as 1 − (number of apoptotic cells with STS and Bcl-xL–DTR − number of apoptotic cells without STS and Bcl-xL–DTR)/(number of apoptotic cells with STS − number of apoptotic cells without STS and Bcl-xL–DTR) except for the nonadherent Jurkat and WEHI7.1 cells, which were counted by using trypan blue dye exclusion and % apoptosis prevention calculated as (number of living cells with STS and Bcl-xL–DTR − number of living cells with STS)/(number of living cells without STS and Bcl-xL–DTR).